Dena Battle

583 total citations
25 papers, 301 citations indexed

About

Dena Battle is a scholar working on Pulmonary and Respiratory Medicine, Economics and Econometrics and Oncology. According to data from OpenAlex, Dena Battle has authored 25 papers receiving a total of 301 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 11 papers in Economics and Econometrics and 8 papers in Oncology. Recurrent topics in Dena Battle's work include Renal cell carcinoma treatment (15 papers), Economic and Financial Impacts of Cancer (11 papers) and Cancer Genomics and Diagnostics (6 papers). Dena Battle is often cited by papers focused on Renal cell carcinoma treatment (15 papers), Economic and Financial Impacts of Cancer (11 papers) and Cancer Genomics and Diagnostics (6 papers). Dena Battle collaborates with scholars based in United States, Germany and Sweden. Dena Battle's co-authors include Sumanta K. Pal, Eric Jonasch, Daniel J. George, Hans J. Hammers, Cristiane Decat Bergerot, Michael B. Atkins, Michael Staehler, Robert A. Figlin, Christopher G. Wood and Thomas E. Hutson and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Journal of Urology.

In The Last Decade

Dena Battle

21 papers receiving 298 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dena Battle United States 7 187 152 96 61 47 25 301
Anna Plym Sweden 12 141 0.8× 124 0.8× 53 0.6× 42 0.7× 23 0.5× 28 330
Chenjie Zeng United States 7 87 0.5× 156 1.0× 46 0.5× 39 0.6× 36 0.8× 12 369
Christopher Su United States 11 114 0.6× 149 1.0× 44 0.5× 23 0.4× 45 1.0× 30 297
U. Otto Germany 11 138 0.7× 98 0.6× 47 0.5× 35 0.6× 53 1.1× 36 278
Maria Lucia Reale Italy 11 179 1.0× 196 1.3× 47 0.5× 51 0.8× 21 0.4× 34 331
Ryan Huey United States 11 58 0.3× 215 1.4× 45 0.5× 49 0.8× 53 1.1× 38 342
Thomas Heisser Germany 12 187 1.0× 325 2.1× 46 0.5× 39 0.6× 71 1.5× 37 450
Rosario Francesco Di Stefano Italy 8 153 0.8× 105 0.7× 70 0.7× 62 1.0× 44 0.9× 25 276
Yngvar Nilssen Norway 11 127 0.7× 210 1.4× 36 0.4× 29 0.5× 35 0.7× 26 334
Derrick S. Haslem United States 9 154 0.8× 208 1.4× 54 0.6× 175 2.9× 96 2.0× 30 459

Countries citing papers authored by Dena Battle

Since Specialization
Citations

This map shows the geographic impact of Dena Battle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dena Battle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dena Battle more than expected).

Fields of papers citing papers by Dena Battle

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dena Battle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dena Battle. The network helps show where Dena Battle may publish in the future.

Co-authorship network of co-authors of Dena Battle

This figure shows the co-authorship network connecting the top 25 collaborators of Dena Battle. A scholar is included among the top collaborators of Dena Battle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dena Battle. Dena Battle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Battle, Dena, et al.. (2024). Real world data on treatment of chromophobe renal cell carcinoma.. Journal of Clinical Oncology. 42(4_suppl). 409–409. 1 indexed citations
3.
Battle, Dena, Nicholas Salgia, Zeynep Büşra Zengin, et al.. (2024). Prevalence of Dietary Modification and Supplement Use in Patients with Metastatic Renal Cell Carcinoma Receiving Systemic Therapy. Nutrients. 16(11). 1630–1630. 1 indexed citations
4.
Battle, Dena, Ulka N. Vaishampayan, Sumanta K. Pal, et al.. (2024). Patient reported outcomes on treatment related side effects with combination therapy in metastatic renal cell carcinoma (RCC).. Journal of Clinical Oncology. 42(16_suppl). e16540–e16540.
5.
Staehler, Michael, et al.. (2023). Financial toxicity in patients with metastatic renal cell carcinoma on combination therapy.. Journal of Clinical Oncology. 41(6_suppl). 651–651. 2 indexed citations
6.
Zhang, Tian, Patrick M. Forde, Ryan J. Sullivan, et al.. (2023). Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs. Journal for ImmunoTherapy of Cancer. 11(5). e006555–e006555. 12 indexed citations
7.
Battle, Dena, Ulka N. Vaishampayan, Pavlos Msaouel, et al.. (2023). Patient priorities and expectations of systemic therapy in metastatic renal cell carcinoma.. Journal of Clinical Oncology. 41(16_suppl). 4560–4560. 2 indexed citations
8.
Battle, Dena, et al.. (2023). Patient perceptions of benefits and risks of adjuvant therapy in renal cell carcinoma.. Journal of Clinical Oncology. 41(6_suppl). 663–663. 1 indexed citations
9.
Mendhiratta, Neil, Vidit Sharma, Neal Patel, et al.. (2021). Decisional Regret and Financial Toxicity among Patients with Benign Renal Masses. Urology Practice. 9(1). 32–39. 1 indexed citations
10.
Bergerot, Cristiane Decat, Errol J. Philip, Paulo Gustavo Bergerot, et al.. (2020). Discrepancies between genitourinary cancer patients' and clinicians' characterization of the Eastern Cooperative Oncology Group performance status. Cancer. 127(3). 354–358. 22 indexed citations
11.
Bergerot, Cristiane Decat, Dena Battle, Errol J. Philip, et al.. (2020). Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma. JCO Oncology Practice. 16(11). e1264–e1271. 17 indexed citations
12.
Staehler, Michael, Dena Battle, Sumanta K. Pal, & Cristiane Decat Bergerot. (2020). Counterbalancing COVID-19 with Cancer Surveillance and Therapy: A Survey of Patients with Renal Cell Carcinoma. European Urology Focus. 7(6). 1355–1362. 6 indexed citations
13.
Battle, Dena, Cristiane Decat Bergerot, Pavlos Msaouel, et al.. (2020). Patient-reported use of marijuana and cannabinoid (CBD) oil in patients with renal cell carcinoma undergoing systemic therapy.. Journal of Clinical Oncology. 38(15_suppl). 5084–5084. 1 indexed citations
14.
Staehler, Michael, Dena Battle, Cristiane Decat Bergerot, Sumanta K. Pal, & David F. Penson. (2020). COVID-19 and financial toxicity in patients with renal cell carcinoma. World Journal of Urology. 39(7). 2559–2565. 17 indexed citations
15.
Battle, Dena, W. Kimryn Rathmell, Eric Jonasch, et al.. (2020). Patient-reported outcomes on treatment-related side effects in renal cell carcinoma.. Journal of Clinical Oncology. 38(6_suppl). 654–654. 4 indexed citations
16.
Bergerot, Cristiane Decat, Dena Battle, Paulo Gustavo Bergerot, et al.. (2019). Sources of Frustration Among Patients Diagnosed With Renal Cell Carcinoma. Frontiers in Oncology. 9. 11–11. 14 indexed citations
17.
Rini, Brian I., Dena Battle, Robert A. Figlin, et al.. (2019). The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). Journal for ImmunoTherapy of Cancer. 7(1). 354–354. 183 indexed citations
18.
Battle, Dena, Daniel J. George, Axel Bex, & Michael Staehler. (2019). Patient perspectives on cytoreductive nephrectomy after CARMENA.. Journal of Clinical Oncology. 37(7_suppl). 658–658. 1 indexed citations
19.
Battle, Dena, Eric Jonasch, Hans J. Hammers, et al.. (2018). Patients perspectives on adjuvant therapy in renal cell carcinoma.. Journal of Clinical Oncology. 36(6_suppl). 644–644. 3 indexed citations
20.
Battle, Dena, Hans J. Hammers, Eric Jonasch, et al.. (2018). Anxiety and patients: Perspectives on surveillance and adjuvant therapy in renal cell carcinoma.. Journal of Clinical Oncology. 36(15_suppl). 4571–4571. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anna Plym Breakdown of academic impact, for papers by Chenjie Zeng Breakdown of academic impact, for papers by Christopher Su Breakdown of academic impact, for papers by U. Otto Breakdown of academic impact, for papers by Maria Lucia Reale Breakdown of academic impact, for papers by Ryan Huey Breakdown of academic impact, for papers by Thomas Heisser Breakdown of academic impact, for papers by Rosario Francesco Di Stefano Breakdown of academic impact, for papers by Yngvar Nilssen Breakdown of academic impact, for papers by Derrick S. Haslem
Rankless by CCL
2026